DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

06978 IMMUNOTECH-B

Closed Add to Porfolio
Index Constituent : None
Major Shareholders Tan Zheng & Associates (25.73%)
Tasly Pharmaceutical Group Co.,Ltd. (15.66%)
[03320] China Resources Pharmaceutical Group Limited (8.33%)
Zhang Junzheng (7.17%)
Greater Bay Area Homeland Development Fund (GP) Limited (6.41%)
Jung Hyun Chul (5.99%)		 Sector Health Care & Biotechnology
Web Site http://www.eaal.net Tel (86 10) 8840-0295
Email N/A Fax N/A
Related Equities N/A
Principal Activities Principally engaged in research and development, manufacturing and commercialisation of immune cell products for treatments of cancers in the PRC.

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top